Article info
PDFClinical and epidemiological research
A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300–600 mg/day versus benzbromarone 100–200 mg/day in patients with gout
- Mr M K Reinders, Department of Clinical Pharmacy, Atrium Medisch Centrum Parkstad, PO Box 4446, 6401 CX Heerlen, The Netherlands; m.reinders{at}atriummc.nl
Citation
A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300–600 mg/day versus benzbromarone 100–200 mg/day in patients with gout
Publication history
- Accepted July 9, 2008
- First published July 16, 2008.
Online issue publication
March 09, 2023
Article Versions
- Previous version (25 October 2017).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
2009 BMJ Publishing Group and European League Against Rheumatism